20 / 62
C o n t e n i d o d i s p o n i b l e e n h t t p : / / www. n e umo l o g i a - p e d i a t r i c a . cl
18
Neumol Pediatr 2016; 11 (1): 15 - 18
Test de sudor en rango intermedio: desafío diagnóstico
REFERENCIAS
1.
Paranjupe S, Zeitlin P. Atypical Cystic Fibrosis and CFTR-
Related Diseases. Clinic Rev Allerg Immunol 2008; 35:116-
123
2.
Grupo Técnico, Programa de Fibrosis Quística Unidad de
Salud Respiratoria , Subsecretaría de Redes Asistenciales
Ministerio de Salud, Programa Nacional de Fibrosis Quística
Orientaciones Técnicas Programáticas para Diagnóstico y
Tratamiento. 2012
3.
Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J,
Girodon
E.etal . Recommendations for the classification of
diseases as CFTR-related disorders. Cyst Fibros 2011; 10
suppl 2: s86-s102
4.
Bush A. Diagnóstico de fibrosis quística. Lo fácil, lo difícil, lo
imposible. Neumol Pediatr 2010; 5: 15-22
5.
Farrell P, Rosenstein B, White T, Accurso F, Castellani C,
Cutting G et al. Guidelines for Diagnosis of Cystic Fibrosis in
Newborns Through Older Adults: Cystic Fibrosis Foundation
Consensus Report. J Pediatr 2008 ; 153:s4-s14
6.
Schram C. Atypical Cystic Fibrosis . Identification in the
primary care setting. Can Fam Physician 2012 ;58:1341-
1345
7.
Levy H, Farrell P. New Challenges in the Diagnosis and
Management of Cystic Fibrosis. J Pediatr 2015; 166:1337-
1340
8.
Groves T, Robinson P, Willey V, Fitzgerald D. Long Term
Outcomes of Children with Intermediate Sweat Chloride
Values in Infancy. J Pediatr 2015;166:1469-1474
9.
Massie J. Clements B and the Australian Paediatric
Respiratory Group. Diagnosis of Cystic Fibrosis After
Newborn Screening: The Australasian Experience-Twenty
Years and Five Million Babies Later: A Consensus Statement
From the Australasian Paediatric Group. Pediatr Pulmonol
2005; 39: 440-446
10. Goubau C, Wilschanski, Skalincka V, Lebecque P, Southern
K, Sermet I et al. Phenotypic characterization of patients
with intermediate sweat chloride values: towards validation
of the European diagnostic algorithm for cystic fibrosis.
Thorax 2009; 64: 683-691
11. Ren C, Desai H, Platt M, Dixon M. Clinical Outcomes in
Infants With CysticFibrosis Transmebrane Regulator (CFTR)
Related Metabolic Syndrome. Pediatr Pulmonol 2011; 46:
1079-1084
12. Borowitz D, Parad R, Sharp J, Sabadosa K, Robinson K, Rock
M et al. Cystic Fibrosis Foundation Practice Guidelines for the
Management of Infants with Cystic Fibrosis Transmembrane
Conductance Regulator-Related Metabolic Syndrome during
the First Two Years of Life and Beyond. J Pediatr 2009; 155:
s 106-s116
13. Mayell S, Munck A, Craig J, Sermet I, Brownlee K, Schwarz
M, Castellani C, Southern K. A European consensus for the
evaluation and management of infants with an equivocal
diagnosis following newborn screening for cystic fibrosis. J
Cyst Fibros 2009;8:71-78
14. Brodlie M, Haq IJ , Roberts K , Elborn JS. Targeted therapies
to improve CFTR function in cystic fibrosis. Gen Med 2015;
7:101-116
15. Temme R, Roggenbuck J, McNamara J. CF versus CRMS
:Diagnostic Challenges in Cystic Fibrosis. Minn Med2012;
10 : 42-44
16. Megan N, Adamski C, Tluczeck A. Clinical practices for
intermediate sweat tests following abnormal cystic fibrosis
newborn screens. J Cyst Fibros 2011; 10: 460-465
17. Parra G, Bozzo R, Palomino MA. Fibrosis quística y enfermedad
del CFTR: a propósito de un caso de traqueobroncopatía
osteocondroplástica. Neumol Pediatr 2016;11:45-49